Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC). Background: KRAS ...

Oral anticoagulant use was associated with a reduced risk for progression of 60% and a reduced risk for death of 76% in ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with ...

The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on ...

Ketones are produced when the body runs low on glucose supplies and starts to burn fat, something that most of us aim for at the gym. This is not a metabolic pathway that one would associate with the ...

Bringing people together is a nonprofit’s strength, according to a Q&A with Chris Meyer, who was named CEO of the Baton Rouge Area Foundation. Meyer returned to Louisiana “armed with important lessons ...